Search: Organigram

Organigram Q1 Revenue Decreases 5% Sequentially to C$43.3 Million

Organigram Reports Record First Quarter Fiscal 2023 Results Achieves record Adjusted Gross Margin and fourth consecutive quarter of positive Adjusted EBITDA FINANCIAL HIGHLIGHTS Net revenue of $43.3 million, up 43% from $30.4 million in the same prior-year period. Adjusted EBITDA1 of $5.6 million, the fourth consecutive quarter of positive Adjusted EBITDA, compared to negative Adjusted EBITDA […] READ MORE: https://www.newcannabisventures.com/organigram-q1-revenue-decreases-5-sequentially-to-c43-3-million/

Organigram Reports Record First Quarter Fiscal 2023 Results

TORONTO–(BUSINESS WIRE)–Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced its results for the first quarter ended November 30, 2022 (“Q1 Fiscal 2023”). All financial information in this press release is expressed in thousands of Canadian dollars (“$”), except for references to $ millions. “Our first quarter of fiscal 2023 demonstrates…

Organigram to Report First Quarter Fiscal 2023 Results on January 12, 2023

TORONTO–(BUSINESS WIRE)–Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today it will report earnings results for its first quarter fiscal 2023 ended November 30, 2022, on Thursday, January 12, 2023, before market open. The Company will host a conference call to discuss its…

Organigram Q4 Revenue Rises 19% Sequentially to C$45.5 Million

Organigram Reports Record Fourth Quarter and Full Year Fiscal 2022 Results Continues trend of record quarterly net revenue and positive Adjusted EBITDA while growing share of adult recreational market Q4 FISCAL 2022 FINANCIAL HIGHLIGHTS Continued record growth in net revenue, reaching $45.5 million, the highest in the history of the Company, up 83% from $24.9 […] READ MORE: https://www.newcannabisventures.com/organigram-q4-revenue-rises-19-sequentially-to-c45-5-million/

Organigram Reports Record Fourth Quarter and Full Year Fiscal 2022 Results

TORONTO–(BUSINESS WIRE)–Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced its results for the fourth quarter and year ended August 31, 2022 (“Q4 Fiscal 2022” or “Fiscal 2022”). “In Fiscal 2022, our innovative product launches, comprehensive retail distribution, sales execution, and operational excellence helped Organigram become a leading consumer products company…

Organigram to Report Annual Fiscal 2022 Results on November 28, 2022

TORONTO–(BUSINESS WIRE)–Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today it will report earnings results for its annual and fourth quarter fiscal 2022 ended August 31, 2022 on Monday, November 28, 2022, after market close. The Company will host a conference call to…

Organigram and InterCure (dba : Canndoc) Sign New International Strategic Agreement Representing Largest Such Deal to Date for Both Companies

TORONTO & HERZILA, Israel–(BUSINESS WIRE)–Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), ( “Organigram”) a leading Canadian licensed producer of cannabis and Canndoc Ltd. (“Canndoc”), a subsidiary of InterCure Ltd. (NASDAQ: INCR) (TSX:INCR.U) (TASE:INCR) (dba Canndoc) Israel’s largest and most established pharmaceutical cannabis producer, today jointly announced that they have entered into a new multi-year agreement (the “New Strategic Agreement”) for…

Organigram Investor BAT Extends Cannabis Exposure by Leading Sanity Group $37.6 Million Capital Raise

Successful closing of Series B Financing Round Berlin-based Sanity Group announces $37.6 Million Series B BERLIN, Sept. 27, 2022 /PRNewswire/ – Leading German cannabis company Sanity Group announced today a $37.6M Series B financing round – Europe’s largest cannabis investment round to date. The round was led by BAT Group* with ongoing commitment from existing Sanity Group investors such as Redalpine and Casa Verde Capital […] READ MORE: https://www.newcannabisventures.com/organigram-investor-bat-extends-cannabis-exposure-by-leading-sanity-group-37-6-million-capital-raise/

How Organigram Became a Top-Tier Canadian Cannabis Company

Exclusive Interview with Organigram CEO Beena Goldenberg Canadian LP Organigram (NASDAQ: OGI) (TSX: OGI) has demonstrated a streak of success in the market as it approaches the end of its fiscal year. The company has had record quarter over quarter growth over the last several quarters, according to CEO Beena Goldenberg. She last sat down […] READ MORE: https://www.newcannabisventures.com/how-organigram-became-a-top-tier-canadian-cannabis-company/

Organigram Q3 Revenue Increases 20% Sequentially to C$38.1 Million

Organigram Reports Third Quarter Fiscal 2022 Results Achieves fourth consecutive quarter of record net revenue and continues growth as a leading Canadian LP in recreational adult use market share HIGHLIGHTS Achieved gross revenue of $55.2 million, up 90% from the same prior-year period and 26% higher than Q2 Fiscal 2022 Continued record growth in net […] READ MORE: https://www.newcannabisventures.com/organigram-q3-revenue-increases-20-sequentially-to-c38-1-million/

Organigram Reports Third Quarter Fiscal 2022 Results

TORONTO–(BUSINESS WIRE)–Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced its results for the third quarter ended May 31, 2022 (“Q3 Fiscal 2022”). “We are pleased to see continued strength in our recreational business with our increasing market share. We achieved record net revenue results which we expect to surpass again…